Literature DB >> 11125236

The Gottfries-Bråne-Steen scale: validity, reliability and application in anti-dementia drug trials.

G Bråne1, C G Gottfries, B Winblad.   

Abstract

Neuropsychological investigation using a comprehensive rating scale is important for the diagnosis and evaluation of dementia patients over time. Requirements for such a scale include accuracy, reliability, sensitivity of the scale over the disease course and simplicity for clinical use by a wide range of healthcare professionals. Ideally, the scale should also be capable of assessing the impact of pharmacological and non-pharmacological treatment regimens on the management of dementia patients. The Gottfries-Bråne-Steen (GBS) Scale is a comprehensive global assessment tool for evaluating dementia symptoms and is based on a semi-structured interview and observation of the patient. The scale consists of subscales measuring intellectual (12 items), emotional (3 items) and activities of daily living, primarily items of self-care (6 items); as well as 6 items of behavioral and psychological symptoms of dementia. This review describes the reliability, validity and sensitivity of the most recent version of the GBS scale since its original publication in 1982. Copyright 2001 S. Karger AG, Basel

Entities:  

Mesh:

Year:  2001        PMID: 11125236     DOI: 10.1159/000051230

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  23 in total

Review 1.  Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials.

Authors:  Hanna Kaduszkiewicz; Thomas Zimmermann; Hans-Peter Beck-Bornholdt; Hendrik van den Bussche
Journal:  BMJ       Date:  2005-08-06

Review 2.  Correlates of response to acetylcholinesterase inhibitor therapy in Alzheimer's disease.

Authors:  Krista L Lanctôt; Nathan Herrmann; Maysoon M LouLou
Journal:  J Psychiatry Neurosci       Date:  2003-01       Impact factor: 6.186

Review 3.  Activities of daily living in patients with dementia: clinical relevance, methods of assessment and effects of treatment.

Authors:  Abhilash K Desai; George T Grossberg; Dharmesh N Sheth
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

4.  Review of Alzheimer's disease scales: is there a need for a new multi-domain scale for therapy evaluation in medical practice?

Authors:  Philippe Robert; Steven Ferris; Serge Gauthier; Ralf Ihl; Bengt Winblad; Frank Tennigkeit
Journal:  Alzheimers Res Ther       Date:  2010-08-26       Impact factor: 6.982

5.  Consequences from use of reminiscence--a randomised intervention study in ten Danish nursing homes.

Authors:  Claire Gudex; Charlotte Horsted; Anders Møller Jensen; Marianne Kjer; Jan Sørensen
Journal:  BMC Geriatr       Date:  2010-06-06       Impact factor: 3.921

Review 6.  Effects of Ginkgo biloba in dementia: systematic review and meta-analysis.

Authors:  Stefan Weinmann; Stephanie Roll; Christoph Schwarzbach; Christoph Vauth; Stefan N Willich
Journal:  BMC Geriatr       Date:  2010-03-17       Impact factor: 3.921

7.  Effectiveness of donepezil in reducing clinical worsening in patients with mild-to-moderate alzheimer's disease.

Authors:  David Wilkinson; Rachel Schindler; Elias Schwam; Gunhild Waldemar; Roy W Jones; Serge Gauthier; Oscar L Lopez; Jeffrey Cummings; Yikang Xu; Howard H Feldman
Journal:  Dement Geriatr Cogn Disord       Date:  2009-09-25       Impact factor: 2.959

8.  Actigraphy in agitated patients with dementia. Monitoring treatment outcomes.

Authors:  R Mahlberg; S Walther
Journal:  Z Gerontol Geriatr       Date:  2007-06       Impact factor: 1.281

Review 9.  Treatment of Alzheimer's disease across the spectrum of severity.

Authors:  Shailaja Shah; William E Reichman
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

10.  A Systematic Review and Meta-Analysis of Ginkgo biloba in Neuropsychiatric Disorders: From Ancient Tradition to Modern-Day Medicine.

Authors:  Natascia Brondino; Annalisa De Silvestri; Simona Re; Niccolò Lanati; Pia Thiemann; Anna Verna; Enzo Emanuele; Pierluigi Politi
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-28       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.